Skip to main content

Table 2 Treatment history

From: SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Treatment history, n (%)

PD-L1 TC ≥ 25%

(n = 132a)

PD-L1 TC < 25%

(n = 264a)

Total (N = 412)

Palliative surgical interventions

44 (33.3)

74 (28.0)

123 (29.9)

Radiotherapy

43 (32.6)

63 (23.9)

113 (27.4)

Chemoradiation therapy

1 (0.8)

0 (0.0)

1 (0.2)

Line of chemotherapy, n

132

264

412

 1st

69 (52.3)

159 (60.2)

238 (57.8)

 2nd

24 (18.2)

55 (20.8)

84 (20.4)

  ≥ 3rd

8 (6.1)

28 (10.6)

42 (10.2)

Type of first-line chemotherapy, n

77

177

266

 Cetuximab

38 (49.4)

91 (51.4)

132 (49.6)

 Cisplatin

41 (53.2)

71 (40.1)

119 (44.7)

 Carboplatin

15 (19.5)

64 (36.2)

84 (31.6)

 Paclitaxel

10 (13.0)

56 (31.6)

67 (25.2)

 Docetaxel

18 (23.4)

22 (12.4)

43 (16.2)

 5-Fluorouracil

35 (45.5)

56 (31.6)

97 (36.5)

Type of second-line chemotherapy

25

60

90

 Cetuximab

8 (32.0)

21 (35.0)

30 (33.3)

 Cisplatin

1 (4.0)

4 (6.7)

5 (5.6)

 Carboplatin

6 (24.0)

13 (21.7)

20 (22.2)

 Paclitaxel

5 (20.0)

20 (33.3)

25 (27.8)

 Docetaxel

7 (28.0)

10 (16.7)

18 (20.0)

 5-Fluorouracil

5 (20.0)

5 (8.3)

10 (11.1)

  1. aPatients with PD-L1 result N = 396
  2. PD-L1 programmed cell death-ligand 1, TC tumor cell